Opinion|Videos|July 1, 2024
Teclistamab Dosing and Adverse Event Prophylaxis Practices
Author(s)Amrita Y. Krishnan, MD, Binod Dhakal, MD, MS
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
Advertisement
Video content above is prompted by the following question(s):
- What factors could contribute to the observed decrease in the onset of new grade ≥3 infections over time, and what are the clinical implications?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
2
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
3
Young Adults With Lung Cancer Often Fall Outside Screening Guidelines
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5